



**IMDRF**

International Medical  
Device Regulators Forum

# **Regulatory Updates on Medical Devices in South Korea**

**Ministry of Food and Drug Safety**

September 2021



# IMDRF

International Medical  
Device Regulators Forum

## Table of Contents

- 01** Major Achievements & Regulatory Initiatives in 2021 and 2022
- 02** New Guidance Documents

# 01

---

## Major Achievements & Regulatory Initiatives in 2021 and 2022



## Quality Advancement of Diagnostic Reagents for COVID-19

- (Quality Management) Products with Emergency Use Authorizations (EUA) and official permits for exports
  - 61 test kits officially approved as the use of EUA-granted tests are expired as of February 1, 2021
- (Support) Consulting assistance in monitoring quality management for IVDs manufacturing sites, etc.
  - \* Relevant consultation on the entities' difficulties and their clinical performance studies, respectively
- (Matching Companies) Support clinical performance evaluation by liaising the entities and medical institutions





## Strengthening Patients' Safety and Management

- **(Proactive Management on Supply Discontinuations)** Imposed duty to report of production or import halt of medical devices which impact people's health in case of supply discontinuation
  - Considering concerns which may cause issues to patients, given that they are critical medical devices in the field
  - Supplies to be discontinued should be reported to the MFDS, and responses to aforementioned is to be provided





## Management of Innovative Medical Devices

- (New Designation) Continued review for designating the identified devices
  - Three (3) MLMDs, One (1) Robotic surgical system, One (1) Focused ultrasound stimulator system, and One (1) Corneal prosthesis have been newly designated
- (Strategies) Stable settlement and revitalization of Innovative Devices system
  - For Improving evaluation system including review criteria for ensuring fairness of the device assessment
  - For Strengthening consulting and priority review, throughout the TPLC for commercialization including the device approval
  - For Introduce customized education for developing the devices and fostering RA professionals





## Extend items according to Environmental & Technical Changes

- (Need) To expand items in the current nomenclature system to respond to medical environment and technology
  - Necessary to keep up with the emerging trend in the medical device industry to be aligned with the 'Medical Field Digital Transformation'
  - \* (e.g.,) support virtual diagnosis • telemedicine based on fourth industrial technology including AI and big data
- (Strategies) To establish new items to expand the scope of safety for medical devices
  - \* Launching new items having new technology, for example software using virtual augmented technology for surgical procedures simulation on screen, and so forth





## To Simplify Regulations on SaMD

- Streamline facility standards of SaMDs manufacturing sites

Item	As-Is	To-Be
<b>For SaMD manufacturing facilities</b>	The same regulations applied for both medical devices and SaMD <ul style="list-style-type: none"><li>• Sites</li><li>• Labs</li><li>• Warehouse</li><li>• Necessary facilities and instruments for manufacturing and quality management</li></ul>	Exemptions for Software medical devices <b>(the "site" is not under regulation)</b> <ul style="list-style-type: none"><li>• <b>Space, facilities and equipment</b> for establishing and implementing QMS</li></ul>
<b>Differential Application for Sites Changes</b>	For location changes <ul style="list-style-type: none"><li>• A copy of consignment agreement (if outsourced manufacturing process or tests)</li><li>• GMP certificates</li></ul>	For location changes <ul style="list-style-type: none"><li>• A copy of consignment agreement (if outsourced manufacturing process or tests)</li><li>• GMP certificates</li><li>• Not applicable to changes in location of SaMD manufacturing sites</li></ul>

- To mitigate regulations on clinical studies of SaMD (long-term strategy)
  - To make less burden by waiving SaMD from the protocol for clinical trials and by being approved by IRB, only



A modern, multi-story building with large windows and a curved facade is visible in the background. A semi-transparent teal rectangle is overlaid on the center of the image, containing the text. The building has a mix of light-colored panels and dark window frames. The sky is a pale, clear blue.

02

---

New Guidance Documents



## Newly Developed Guidance Documents for Industry

### COVID-19

- Guidance on the Review & Approval of IVDs for COVID-19 (4th Edition)

### Pre-market

- Guidance on the Review & Approval of Power-Assistance Device for Wheelchair
- Guidance on the Review & Approval of Medical Device with Virtual Reality and Augmented Reality Technology (2<sup>nd</sup> Edition)
- Guidance on the Review & Approval of Medical Device with Plasma Generator for Skin
- Guidance on GLP Consideration for Biocompatibility Test
- Guidance on Clinical Performance for IVDs

### GMP

- Guidance on the Usability of Biomaterial for Graft/Prosthesis
- Guidance on the Usability of Robotic-guidance Rehabilitation Exerciser

### Post-market

- Manual for Reducing Foreign Object Debris of Syringe



**IMDRF**

International Medical  
Device Regulators Forum

Thank you for your attention



Ministry of Food and  
Drug Safety